Shares of Hypermarcas (OTCMKTS:HYPMY – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $3.94, but opened at $4.0990. Hypermarcas shares last traded at $3.91, with a volume of 3,190 shares traded.
Analyst Ratings Changes
Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.
View Our Latest Report on Hypermarcas
Hypermarcas Price Performance
The stock has a market cap of $2.72 billion, a P/E ratio of 7.43 and a beta of 0.78. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. The company’s fifty day simple moving average is $4.61 and its 200-day simple moving average is $4.40.
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its quarterly earnings data on Wednesday, November 11th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. Hypermarcas had a net margin of 20.07% and a return on equity of 12.58%. The company had revenue of $473.13 million during the quarter, compared to analysts’ expectations of $450.75 million. As a group, sell-side analysts forecast that Hypermarcas will post 0.50 EPS for the current year.
Hypermarcas Company Profile
Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo QuĂmica and Mantecorp.
Read More
- Five stocks we like better than Hypermarcas
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
